Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy
Pharmacological Research · 2024
DOI: 10.1016/j.phrs.2024.107352 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2024. Verfasst von Beatrice Spokeviciute und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, University of Torino, Turin, Italy. Hauptthemen laut MEDLINE: Extracellular Vesicles, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
A cutting-edge approach in cell-based immunotherapy for combating resistant cancer involves genetically engineered chimeric antigen receptor T (CAR-T) lymphocytes. In recent years, these therapies have demonstrated effectiveness, leading to their commercialization and clinical application against certain types of cancer. However, CAR-T therapy faces limitations, such as the immunosuppressive tumour microenvironment (TME) that can render CAR-T cells ineffective, and the adverse side effects of the therapy, including cytokine release syndrome (CRS). Extracellular vesicles (EVs) are a diverse group of membrane-bound particles released into the extracellular environment by virtually all cell types. They are essential for intercellular communication, transferring cargoes such as proteins, lipids, various types of RNAs, and DNA fragments to target cells, traversing biological barriers both locally and systemically. EVs play roles in numerous physiological processes, with those from both immune and non-immune cells capable of modulating the immune system through activation or suppression. Leveraging this capability of EVs to enhance CAR-T cell therapy could represent a significant advancement in overcoming its current limitations. This review examines the current landscape of CAR-T cell immunotherapy and explores the potential role of EVs in augmenting its therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, University of Torino, Turin, Italy.
- Department of Medical Sciences, University of Torino, Turin, Italy. Electronic address: mariafelice.brizzi@unito.it.
Zitieren
APA
Spokeviciute, B., Kholia, S., & Brizzi, M. F. (2024). Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107352
Vancouver
Spokeviciute B, Kholia S, Brizzi MF. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107352
BibTeX
@article{Spokeviciute2024,
author = {Spokeviciute, Beatrice and Kholia, Sharad and Brizzi, Maria Felice},
title = {Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy},
journal = {Pharmacological Research},
year = {2024},
doi = {10.1016/j.phrs.2024.107352}
}
EUVIMED